Researchers published a Nature Communications study showing that the m6A RNA demethylase ALKBH5 sustains colorectal cancer stemness and drives chemoresistance. The team demonstrated that genetic or pharmacologic inhibition of ALKBH5 reduced tumor‑initiating capacity and sensitized cells to chemotherapy in preclinical models. The paper positions ALKBH5 as a druggable node in epitranscriptomic control of cancer stem cells. For translational teams, the findings flag ALKBH5 inhibitors and combination regimens with standard cytotoxics or targeted agents as priority development paths; validation in patient‑derived models and safety profiling will determine clinical viability.